Infectious Disease PGx Panel

The Infectious Disease PGx Panel is intended for individuals receiving antimicrobial, antiviral, or antifungal therapies who may benefit from personalized pharmacogenetic-guided medication management. This panel evaluates clinically relevant genetic variants associated with drug metabolism, efficacy, and hypersensitivity risk for medications commonly used in the treatment of infectious diseases. Pharmacogenetic testing may help guide medication selection and dosing, reduce the risk of severe adverse drug reactions, improve therapeutic response, and support safer, more effective individualized treatment strategies. Upon completion of testing, patients receive an interpretive pharmacogenetic report and certificate summarizing clinically relevant results and medication-related findings to support ongoing care and future treatment decisions.

Turnaround Time: 3-7 business days
Preferred specimens: Saliva
Alternate specimens: Buccal Swab

Testing Kit Request Form

Many medications used to treat infectious diseases are metabolized by liver enzymes including CYP2C19. Trough voriconazole concentrations found to be lower in patients with CYP2C19 ultra-rapid metabolizers compared to poor metabolizers resulting in delay in achieving therapeutic level. This may be critical in life-threatening infections such as invasive aspergillosis. CPIC guideline recommends that patients with CYP2C19 ultra-rapid or rapid metabolizer status to receive an alternative agent other than voriconazole as therapeutic level may not be achievable. Patients with CYP2C19 poor metabolizer status should use an alternative agent due to high risk for developing adverse effects. It is well described that HLA-B*5701 screening reduces the risk of hypersensitivity reaction to abacavir.

Many medications used to treat infectious diseases are metabolized by liver enzymes including CYP2C19. Trough voriconazole concentrations found to be lower in patients with CYP2C19 ultra-rapid metabolizers compared to poor metabolizers resulting in delay in achieving therapeutic level. This may be critical in life-threatening infections such as invasive aspergillosis. CPIC guideline recommends that patients with CYP2C19 ultra-rapid or rapid metabolizer status to receive an alternative agent other than voriconazole as therapeutic level may not be achievable. Patients with CYP2C19 poor metabolizer status should use an alternative agent due to high risk for developing adverse effects.
It is well described that HLA-B*5701 screening reduces the risk of hypersensitivity reaction to abacavir.

Frequency of Cytochrome P450 (CYP2C19) Metabolizer Types in the Population